William Berry

Dr. William Berry

Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2013 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WBWilliam Berry
William Berry
RJRalf Janknecht
Ralf Janknecht
Lysine methylation is one of the most prominent histone posttranslational modifications that regulate chromatin structure. Changes in histone lysine methylation status have been observed during cancer formation, which is thought to be a consequence of the dysregulation of histone lysine methyltransferases or the opposing demethylases. KDM4/JMJD2 proteins are demethylases that target histone H3 on lysines 9 and 36 and histone H1.4 on lysine 26. This protein family consists of three ∼130-kDa proteins (KDM4A-C) and KDM4D/JMJD2D, which is half the size, lacks the double PHD and Tudor domains that are epigenome readers and present in the other KDM4 proteins, and has a different substrate specificity. Various studies have shown that KDM4A/JMJD2A, KDM4B/JMJD2B, and/or KDM4C/JMJD2C are overexpressed in breast, colorectal, lung, prostate, and other tumors and are required for efficient cancer cell growth. In part, this may be due to their ability to modulate transcription factors such as the androgen and estrogen receptor. Thus, KDM4 proteins present themselves as novel potential drug targets. Accordingly, multiple attempts are under way to develop KDM4 inhibitors, which could complement the existing arsenal of epigenetic drugs that are currently limited to DNA methyltransferases and histone deacetylases. Cancer Res; 73(10); 2936–42. ©2013 AACR.

16 July 2015 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
BHBethany Hannafon
Bethany Hannafon
KCKarla J. Carpenter
Karla J. Carpenter
WBWilliam Berry
William Berry
RJRalf Janknecht
Ralf Janknecht
WDWilliam C. Dooley
William C. Dooley
Wei-Qun DingWei-Qun Ding
Wei-Qun Ding
Docosahexaenoic acid (DHA) is a natural compound with anticancer and anti-angiogenesis activity that is currently under investigation as both a preventative agent and an adjuvant to breast cancer therapy. However, the precise mechanisms of DHA’s anticancer activities are unclear. It is understood that the intercommunication between cancer cells and their microenvironment is essential to tumor angiogenesis. Exosomes are extracellular vesicles that are important mediators of intercellular communication and play a role in promoting angiogenesis. However, very little is known about the contribution of breast cancer exosomes to tumor angiogenesis or whether exosomes can mediate DHA’s anticancer action. Exosomes were collected from MCF7 and MDA-MB-231 breast cancer cells after treatment with DHA. We observed an increase in exosome secretion and exosome microRNA contents from the DHA-treated cells. The expression of 83 microRNAs in the MCF7 exosomes was altered by DHA (>2-fold). The most abundant exosome microRNAs (let-7a, miR-23b, miR-27a/b, miR-21, let-7, and miR-320b) are known to have anti-cancer and/or anti-angiogenic activity. These microRNAs were also increased by DHA treatment in the exosomes from other breast cancer lines (MDA-MB-231, ZR751 and BT20), but not in exosomes from normal breast cells (MCF10A). When DHA-treated MCF7 cells were co-cultured with or their exosomes were directly applied to endothelial cell cultures, we observed an increase in the expression of these microRNAs in the endothelial cells. Furthermore, overexpression of miR-23b and miR-320b in endothelial cells decreased the expression of their pro-angiogenic target genes (PLAU, AMOTL1, NRP1 and ETS2) and significantly inhibited tube formation by endothelial cells, suggesting that the microRNAs transferred by exosomes mediate DHA’s anti-angiogenic action. These effects could be reversed by knockdown of the Rab GTPase, Rab27A, which controls exosome release. We conclude that DHA alters breast cancer exosome secretion and microRNA contents, which leads to the inhibition of angiogenesis. Our data demonstrate that breast cancer exosome signaling can be targeted to inhibit tumor angiogenesis and provide new insight into DHA’s anticancer action, further supporting its use in cancer therapy.

4 September 2012 in International Journal of Oncology
Verified
Journal Article
Closed access
WBWilliam Berry
William Berry
SSSook Shin
Sook Shin
SLStan A. Lightfoot
Stan A. Lightfoot
RJRalf Janknecht
Ralf Janknecht
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

6 May 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
NWNathaniel Weygant
Nathaniel Weygant
DQDongfeng Qu
Dongfeng Qu
WBWilliam Berry
William Berry
RMRandal May
Randal May
PCParthasarathy Chandrakesan
Parthasarathy Chandrakesan
CHCourtney W Houchen
Courtney W Houchen
Doublecortin-like kinase 1 (DCLK1) is emerging as a tumor specific stem cell marker in colorectal and pancreatic cancer. Previous in vitro and in vivo studies have demonstrated the therapeutic effects of inhibiting DCLK1 with small interfering RNA (siRNA) as well as genetically targeting the DCLK1+ cell for deletion. However, the effects of inhibiting DCLK1 kinase activity have not been studied directly. Therefore, we assessed the effects of inhibiting DCLK1 kinase activity using the novel small molecule kinase inhibitor, LRRK2-IN-1, which demonstrates significant affinity for DCLK1.

1 December 2011 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
TKTae‐Dong Kim
Tae‐Dong Kim
SSSook Shin
Sook Shin
WBWilliam Berry
William Berry
SOSangphil Oh
Sangphil Oh
RJRalf Janknecht
Ralf Janknecht

15 October 2017 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
GOGary B. O'Mealey
Gary B. O'Mealey
KPKendra S. Plafker
Kendra S. Plafker
WBWilliam Berry
William Berry
RJRalf Janknecht
Ralf Janknecht
JCJefferson Y. Chan
Jefferson Y. Chan
SPScott M. Plafker
Scott M. Plafker
The Nrf2 transcription factor is a master regulator of the cellular anti-stress response. A population of the transcription factor associates with the mitochondria through a complex with KEAP1 and the mitochondrial outer membrane histidine phosphatase, PGAM5. To determine the function of this mitochondrial complex, we knocked down each component and assessed mitochondrial morphology and distribution. We discovered that depletion of Nrf2 or PGAM5, but not KEAP1, inhibits mitochondrial retrograde trafficking induced by proteasome inhibition. Mechanistically, this disrupted motility results from aberrant degradation of Miro2, a mitochondrial GTPase that links mitochondria to microtubules. Rescue experiments demonstrate that this Miro2 degradation involves the KEAP1–cullin-3 E3 ubiquitin ligase and the proteasome. These data are consistent with a model in which an intact complex of PGAM5–KEAP1–Nrf2 preserves mitochondrial motility by suppressing dominant-negative KEAP1 activity. These data further provide a mechanistic explanation for how age-dependent declines in Nrf2 expression impact mitochondrial motility and induce functional deficits commonly linked to neurodegeneration.